Vertex Pharmaceuticals IncorporNasdaq: VRTX
Health Care · Biotechnology
$425.02
-0.55%
Vol: 542K
Research Digest
Friday, May 1, 2026
FDA approves ALYFTREK and TRIKAFTA label extensions to ~95% of CF patients; povetacicept shows 52% proteinuria reduction in Phase 3.
Vertex received FDA approval for ALYFTREK and TRIKAFTA label extensions to ~95% of US cystic fibrosis patients. Reported positive Week 36 RAINIER Phase 3 trial of povetacicept for IgA nephropathy: 52% reduction in proteinuria and 49.8% reduction vs placebo. Canaccord lowered PT to $437 from $441. Consensus rating Hold with $441 PT. Q1 2026 earnings May 4, expecting $2.98B revenue and $4.20 EPS.
Previous Market Intelligence
13 daysApr 30Vertex announces positive Week 36 interim data for povetacicept in Phase 3 RAINIER trial showing 52% proteinuria reduction; FDA expands TRIKAFTA labels.Positive▶
Vertex reported positive Week 36 interim analysis from Phase 3 RAINIER trial of povetacicept for IgA nephropathy, achieving 52% reduction in proteinuria from baseline and statistically significant 49.8% reduction versus placebo. FDA approved label extensions for TRIKAFTA and ALYFTREK, expanding availability to approximately 95% of all people with cystic fibrosis in the US. Company expects Q1 revenue of $2.98 billion and EPS of $4.20. Analysts maintain Buy consensus with $546 average target (28.59% upside), though Canaccord reduced target to $437 from $441.
Apr 16Vertex gains FDA approval for CFTR label expansion; raises 2026 guidance to $12.95-13.1BPositive▶
Vertex announced FDA approval of expanded use for ALYFTREK and TRIKAFTA, making cystic fibrosis therapies available to ~95% of U.S. patients. Positive Week 36 interim data from RAINIER Phase 3 trial of povetacicept showed 52% proteinuria reduction. Management raised 2026 revenue guidance to $12.95-13.1B. Morgan Stanley issued Buy rating on April 10; RBC raised PT to $543. Upcoming earnings May 4. Strategic licensing deal with Halozyme announced for Hypercon technology.
Apr 15Vertex Pharmaceuticals gains FDA label expansion for ALYFTREK and TRIKAFTA, extending CF treatment to 95% of patients.Positive▶
In early April 2026, Vertex announced US FDA approval for expanded label use of ALYFTREK and TRIKAFTA cystic fibrosis therapies, making CFTR modulator treatment available to approximately 95% of people with cystic fibrosis in the United States. The approvals were supported by data from 564 variants for ALYFTREK and 521 variants for TRIKAFTA. Additionally, Vertex completed a rolling Biologics License Application for povetacicept targeting IgA nephropathy. Q1 2026 financial results are scheduled for May 4. Morgan Stanley raised its price target from $596 to $612, with a bullish consensus at $558.
Apr 14FDA approves label extensions for ALYFTREK and TRIKAFTA; RAINIER trial shows positive povetacicept data; 2026 guidance $12.95B-$13.1B.Positive▶
Vertex announced FDA approval for label extensions expanding ALYFTREK and TRIKAFTA availability to approximately 95% of all people with cystic fibrosis in the US. Positive Week 36 interim results from Phase 3 RAINIER trial of povetacicept for IgA nephropathy showed 52% proteinuria reduction. Full BLA submission planned by end-March. 2025 revenue reached $12.0 billion; 2026 guidance of $12.95B-$13.1B. Wall Street has 27 Buy, 4 Hold, 2 Sell ratings with $558 average price target.
Apr 13FDA approves expanded use of ALYFTREK and TRIKAFTA for cystic fibrosis, broadening treatment eligibility to ~95% of US CF patients.Positive▶
Vertex Pharmaceuticals received FDA approval in early April 2026 for expanded label extensions of ALYFTREK and TRIKAFTA, extending availability to approximately 95% of all people with cystic fibrosis in the US. The company also completed a rolling Biologics License Application for povetacicept in IgA nephropathy using a priority review voucher, signaling expansion into kidney disease. Morgan Stanley raised its price target to $612 from $596 on April 10. Q1 2026 earnings are expected May 4, with consensus EPS of $4.43.
Apr 10Vertex Pharmaceuticals expands CF approvals and files for IgAN therapy amid Q1 earnings guidance reset.Positive▶
Vertex announced expanded FDA approvals for cystic fibrosis therapies ALYFTREK and TRIKAFTA in early April, expanding to approximately 95% of CF patients. The company also filed for accelerated approval of povetacicept for immunoglobulin A nephropathy using a priority review voucher. Separately, Vertex signed a licensing deal with Halozyme for Hypercon technology with $15 million upfront payments. Q1 2026 earnings are scheduled for May 4.
Apr 9Vertex announces positive Week 36 interim results for IgA nephropathy therapy povetacicept in RAINIER trialPositive▶
Vertex announced positive Week 36 interim analysis results from the RAINIER Phase 3 trial of povetacicept, an engineered fusion protein dual inhibitor of BAFF and APRIL cytokines, showing a statistically significant 49.8% UPCR (urine protein to creatinine ratio) reduction compared to placebo in IgA nephropathy. In April 2026, the FDA approved label extensions for ALYFTREK and TRIKAFTA, expanding availability to ~95% of all people with CF in the United States. The company reported 2025 total revenues of $12 billion, representing 9% growth driven by CF medicines and CASGEVY/JOURNAVX sales. Vertex is preparing for Q1 2026 earnings announcement on May 4, 2026, with continued focus on executing the CF franchise and bringing CASGEVY to global markets.
Apr 8FDA approves label extensions for ALYFTREK and TRIKAFTA, expanding CF treatment reachPositive▶
Vertex Pharmaceuticals announced U.S. FDA approval for label extensions of ALYFTREK and TRIKAFTA on April 1, 2026, expanding availability to approximately 95% of all people with cystic fibrosis in the United States. The company also announced positive Week 36 interim analysis results for the RAINIER Phase 3 Trial of Povetacicept in adults with IgA Nephropathy. Vertex is presenting new efficacy data on JOURNAVX for acute pain management. The company will report Q1 2026 financial results on May 4, 2026, following market close. Recent analyst consensus forecasts $4.43 EPS next quarter.
Apr 7Vertex reports positive RAINIER trial interim results for IgA nephropathy therapy; Q1 2026 earnings due May 4Positive▶
Vertex announced positive Week 36 interim analysis results from the Phase 3 RAINIER trial of povetacicept, showing 52% proteinuria reduction and 49.8% UPCR reduction versus placebo. The company received FDA approval for expanded CF treatment labels, increasing availability to 95% of US CF patients. Vertex will report Q1 2026 financial results on May 4 after market close. Despite a 1.9% stock price drop, analysts project strong earnings growth with $4.43 EPS expected. The stock trades at $438.71.
Apr 6Vertex FDA expands ALYFTREK and TRIKAFTA labels to ~95% of CF patients; RAINIER positive interim.Positive▶
Vertex announced FDA approvals expanding ALYFTREK and TRIKAFTA to cover ~95% of CF patients in U.S. Positive Week 36 interim analysis for RAINIER Phase 3 of povetacicept in IgA Nephropathy. EVP Joy Liu sold 978 shares April 1 for $439,288. Stock at $448. Avg PT $548.50.
Apr 3Vertex Pharmaceuticals receives FDA approval for expanded labels of Alyftrek and Trikafta, now available to 95% of CF patients.Positive▶
Vertex achieved FDA approval for label expansions of ALYFTREK and TRIKAFTA, extending eligibility to approximately 95% of U.S. people with cystic fibrosis. Positive Phase 3 RAINIER trial results for povetacicept in IgA Nephropathy showed 52% reduction in proteinuria. BLA submission expected by end of March with priority review voucher. Wells Fargo raised price target to $550. Analyst consensus is Buy with $537.64 price target (15.50% upside).
Apr 1Vertex announced positive Week 36 interim analysis of povetacicept Phase 3 RAINIER trial with 52% proteinuria reduction and filed rolling BLA for FDA accelerated approval.Positive▶
Vertex Pharmaceuticals reported positive interim results from the Phase 3 RAINIER trial for povetacicept, achieving 52% proteinuria reduction from baseline and 49.8% reduction in UPCR versus placebo. The company filed a rolling BLA to the FDA seeking accelerated approval for IgA nephropathy treatment using a priority review voucher. Pipeline includes zimislecel for Type 1 diabetes with approval request planned this year. The company maintains seven approved medicines. Recent analyst upgrades from Oppenheimer, Bank of America, and Wells Fargo.
Mar 31Vertex positive RAINIER Phase 3 for povetacicept in IgA nephropathy; BLA submission by March 31.Positive▶
Vertex positive Phase 3 RAINIER results for povetacicept in IgA nephropathy. BLA submission by end of March 2026. Potential FDA approval by year-end 2026. Journavx and Casgevy expected $500M+ in 2026. Analyst targets $330-$641. Down 10% over 12 months.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| ABBVABBVIE | $207.05 | -2.02% | +2.2% | 13.1x | — | $373.8B |
| AMGNAMGEN | $330.27 | -4.62% | +1.1% | 14.8x | 0.47 | $186.7B |
| GILDGILEAD | $131.80 | +0.73% | -6.6% | 13.6x | 0.40 | $162.4B |
| VRTXVERTEX | $425.02 | -0.55% | -1.6% | 19.6x | 0.37 | $108.7B |
| REGNREGENERON | $702.19 | -0.69% | -7.3% | 13.0x | 0.40 | $74.1B |
| BIIBBIOGEN | $187.16 | -1.12% | +9.8% | 11.9x | 0.16 | $27.9B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.